Investors / United States / Mission BioCapital
Mission BioCapital
Venture capital · San Francisco, CA, United States · North America
Mission BioCapital is a life science venture firm that provides early-stage capital to life science startups and operates shared lab space through affiliated incubators. It also runs the Platinum Program, which awards capital, a lab bench, drug discovery services, legal advising and mentorship to early-stage biomedical companies.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechdrug discoveryincubatorsearly stage
Your fit with Mission BioCapital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsMission BioCapital lists 51 checked portfolio companies on its own site and is named in 9 funding rounds, 1 of them as lead. Its most frequent entry is Seed, 33% of the companies with a known first round. Its largest themes are Healthcare & Biotech (90%), AI & Machine Learning (4%) and E-commerce & Marketplaces (2%). 91% of its companies are based in United States. It invests most often alongside Berkeley Catalyst Fund, Mission Bay Capital and Sanofi Ventures.
Counts come from funding rounds that name Mission BioCapital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Mission BioCapital's whole history. Rounds on record name 9 companies; its own site lists 51. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 33% |
| Series B | 22% |
| Growth | 11% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 8 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 85th | 52 companies |
| Recent activity | 93th | 8 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 72th | 8% of companies confirmed by a round |
| Sector focus | 96th | 90% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Berkeley Catalyst Fund | 4 |
| Mission Bay Capital | 4 |
| Sanofi Ventures | 4 |
| Dolby Family Ventures | 3 |
| Lightspeed Venture Partners | 3 |
| Pappas Capital | 3 |
| RA Capital | 3 |
| 4BIO Capital | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4996%
- No longer answers00%
- Points to another company24%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 90% | 15% |
| AI & Machine Learning | 4% | 18% |
| E-commerce & Marketplaces | 2% | 5% |
| Food & Agriculture | 2% | 3% |
| Climate & Energy | 2% | 1% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Berkeley Catalyst Fund
Compare Mission BioCapital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Mission BioCapital| Date | Company | Stage |
|---|---|---|
| 10 Nov 2026 | Series A | |
| 29 Oct 2026 | Series C+ | |
| 29 Sept 2026 | Series A Led | |
| 8 Sept 2026 | Seed | |
| 1 Apr 2026 | Seed | |
| 8 Jan 2026 | Seed | |
| 8 Jan 2026 | Series B | |
| 7 Jan 2026 | Series B |
Round details for Mission BioCapital
Amounts, full round histories and every co-investor in Mission BioCapital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
51 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| The company designs and develops a new class of miniprotein medicines using artificial intelligence and lab validation. | Healthcare & Biotech | Portfolio page | ||
| Alector develops therapies for neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
| Alessa Therapeutics is developing a proprietary drug-delivery platform for sustained and localized release of clinically proven therapies to effectively treat early-stage prostate cancer | Healthcare & Biotech | Portfolio page | ||
| The company is developing a new class of medicines that can interact with previously undruggable targets | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| ARase Therapeutics develops first-in-class therapeutics targeting ADP-ribose Hydrolases for cancer treatment | Healthcare & Biotech | Portfolio page | ||
| Asher Bio develops immunotherapies that selectively activate specific immune cell types to treat diseases. | Healthcare & Biotech | Portfolio page | ||
| The company pioneers and manufactures biomaterials to create high-quality solutions for various personal care formulations. | Healthcare & Biotech | Portfolio page | ||
| Breye Therapeutics develops novel, orally administered ophthalmology drugs to meet the needs of patients at risk of vision loss. | Healthcare & Biotech | Sept 2026Series A | Funding round | |
| Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. | Healthcare & Biotech | Portfolio page | ||
| Cavalry Biosciences develops precision medicines based on IGF-1, a growth factor, to treat various diseases | Healthcare & Biotech | Portfolio page | ||
| Circle Pharma harnesses the power of macrocycles to transform the treatment of cancer. | Healthcare & Biotech | Portfolio page | ||
| The company is developing a new class of RNA therapeutics to revolutionize cancer therapy. | Healthcare & Biotech | Sept 2026Seed | Funding round | |
| Dren Bio is a clinical-stage biopharmaceutical company that discovers and develops novel antibody therapeutics for cancer and other serious diseases. | Healthcare & Biotech | Oct 2026Series C+ | Page + round | |
| The company is a clinical stage biopharmaceutical company. | Healthcare & Biotech | Portfolio page | ||
| Eikonizo Therapeutics is developing disease-modifying therapies by creating brain-penetrant and peripheral small molecules to improve the lives of people impacted by neurodegenerative, cardiorenal and other diseases. | Healthcare & Biotech | Portfolio page | ||
| Enodia Therapeutics develops novel small-molecule therapies for targeted protein degradation at the point of synthesis | Healthcare & Biotech | Jan 2026Seed | Funding round | |
| EpiBiologics develops medicines that use bispecific antibodies to selectively degrade disease-causing extracellular proteins | Healthcare & Biotech | Jan 2026Series B | Page + round | |
| The company creates small-molecule opioid medicines for pain management and Opioid Use Disorder (OUD). | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- missionbiocapital.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 28 Oct 2025
- Companies checked
- 51
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Mission BioCapital's profile as data
Pull Mission BioCapital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/missionbiocapital.com
# also
GET /v1/firms/missionbiocapital.com/portfolio
GET /v1/firms/missionbiocapital.com/coinvestors
GET /v1/firms/missionbiocapital.com/news